EDIT Key Statistics, Chart & Performance
The current stock price of EDIT is 2.07 USD. In the past month the price decreased by -20.38%. In the past year, price increased by 64.29%.
EDIT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About EDIT
Company Profile
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 246 full-time employees. The company went IPO on 2016-02-03. The company has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. The company is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
Company Info
EDITAS MEDICINE INC
11 Hurley St
Cambridge MASSACHUSETTS 02141 US
CEO: James C. Mullen
Employees: 246
Phone: 16174019000
EDITAS MEDICINE INC / EDIT FAQ
Can you describe the business of EDITAS MEDICINE INC?
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 246 full-time employees. The company went IPO on 2016-02-03. The company has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. The company is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
What is the current price of EDIT stock?
The current stock price of EDIT is 2.07 USD. The price decreased by -3.27% in the last trading session.
Does EDITAS MEDICINE INC pay dividends?
EDIT does not pay a dividend.
How is the ChartMill rating for EDITAS MEDICINE INC?
EDIT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is EDITAS MEDICINE INC worth?
EDITAS MEDICINE INC (EDIT) has a market capitalization of 202.07M USD. This makes EDIT a Micro Cap stock.
What is the ownership structure of EDITAS MEDICINE INC (EDIT)?
You can find the ownership structure of EDITAS MEDICINE INC (EDIT) on the Ownership tab.
What is the Short Interest ratio of EDITAS MEDICINE INC (EDIT) stock?
The outstanding short interest for EDITAS MEDICINE INC (EDIT) is 11.46% of its float.
EDIT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to EDIT. When comparing the yearly performance of all stocks, EDIT turns out to be only a medium performer in the overall market: it outperformed 61.19% of all stocks.
EDIT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to EDIT. EDIT may be in some trouble as it scores bad on both profitability and health.
EDIT Financial Highlights
Over the last trailing twelve months EDIT reported a non-GAAP Earnings per Share(EPS) of -2.38. The EPS increased by 7.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -99.05% | ||
| ROE | -1485.43% | ||
| Debt/Equity | 4.02 |
EDIT Forecast & Estimates
21 analysts have analysed EDIT and the average price target is 5.04 USD. This implies a price increase of 143.3% is expected in the next year compared to the current price of 2.07.
For the next year, analysts expect an EPS growth of 28.52% and a revenue growth -41.77% for EDIT